Amylyx Pharmaceuticals announced it has completed enrollment for the Phase 2 clinical trial of AMX0035 for treating Alzheimer’s disease. The placebo-controlled trial, PEGASUS (NCT03533257), will evaluate the compound’s safety and tolerability among patients with late mild cognitive impairment or early dementia due to Alzheimer’s disease. Other study endpoints (goals) include the compound’s effects on Alzheimer’s biomarkers (methods to measure disease) and on cognitive and functional abilities. Amylyx said it expects to present study data in the first…
You must be logged in to read/download the full post.
The post Amylyx Completes Enrollment in PEGASUS Trial of AMX0035 for Alzheimer’s appeared first on BioNewsFeeds.